EUCTR2008-001369-27-IT进行中（未招募）不适用
PHASE II STUDY OF LIPOSOME-ENCAPSULATED DOXORUBICIN PLUS PACLITAXEL AND TRASTUZUMAB AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY-ADVANCED BREAST CANCER - PACLIDOX 07
AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE0 个研究点开始时间: 2009年3月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Histologically confirmed breast cancer. - Operable breast cancer patients (T>2 cm, cT2-3, N0-N2, M0) or potentially operable, locally advanced breast cancer patients (T4, N0-2, M0) or inflammatory breast cancer patients (T4d, N0-2, M0), with or without HER2 overexpression or amplificationu` - Hercept-test (DAKO) or FISH performed - Age > 18 and < 75 - ECOG performance status 0-1 - Life expectancy >3 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Prior chemotherapy. - History of prior malignancy in the last 10 years (other than non-melanoma skin cancer or excised cervical carcinoma in situ). - Other serious illness or medical condition - Congestive hearth failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction, uncontrolled high risk hypertension or arrhythmia - Pregnant and lactating women
研究者
相似试验
进行中（未招募）
不适用
A phase II study of Pegylated Liposomal Doxorubicin PLD as preoperative treatment for elderly patients with locally advanced primary breast cancer. - NDocally advanced breast cancerMedDRA version: 6.1Level: PTClassification code 10057654EUCTR2005-005039-86-ITISTITUTO EUROPEO DI ONCOLOGIA30
招募中
2 期
A Phase II Trial of Liposomal Doxorubicin (PLD, DOXILTM) as 3rd Line Treatment in Relapsed, Plutinum - resistant Ovarian CancerOvarian CancerJPRN-UMIN000002814Osaka University Faculty of Medicine Department of obstetrics and gynecology43
已完成
2 期
A Phase II Trial of Liposomal Doxorubicin (PLD) + Carboplatin (CBDCA) as Treatment in Relapsed, Plutinum-sensitive Ovarian CancerOvarian cancerJPRN-UMIN000003944Osaka University Graduate School of Medicine Department of Obstetrics and Gynecology85
已完成
3 期
Randomized Phase III Trail of Liposomal Doxorubicin(PLD)50mg/m2 versus Liposomal Doxorubicin(PLD)40mg/m2 in Patients with Platinum-Refractory and -Resistant Mullerian Carcinoma (Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma).Patients with platinum-refractory and -resistant Mullerian Carcinoma (epithelial ovarian, fallopian tube, primary peritoneal carcinoma)JPRN-UMIN000003130Japanese Gynecologic Oncology Group470
进行中（未招募）
不适用
ON PEGILATED LIPOSOMIAL DOXORUBICIN (TLC D-99) IN ASSOCIATION WITH IFOSFAMIDE IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA - NDMETASTATIC SOFT TISSUE SARCOMASMedDRA version: 9.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasEUCTR2008-003316-36-ITCENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO